索拉菲尼联合TACE治疗肝癌术后复发的临床疗效分析

目的 对比肝动脉化疗栓塞与联合索拉非尼治疗肝癌术后复发患者的临床疗效。方法 将2013年1月~2015年1月笔者医院收治的56例肝癌术后复发患者，根据治疗方式不同分为两组，对照组26例仅单纯行TACE治疗，观察组30例在行TACE治疗后1周开始服用索拉非尼，治疗后对患者的近期疗效、中位生存期及肝外转移情况进行随访。结果 治疗1个月后，观察组总有效率（66.7%）优于对照组（38.5%），差异有统计学意义（P<0.05）；随访至2016年12月，观察组中位生存时间15.8个月，大于对照组10.8个月（P<0.05），观察组肝外转移率3.33%小于对照组23.08%（P<0.05）。结论 TACE联合索拉非尼可有效延长肝癌术后复发患者肿瘤进展期，提高生存时间，降低远处转移率，有望使肝癌术后复发患者获益。

Clinical Analysis of Sorafenib Combined with TACE in the Treatment of Postoperative Recurrence in Patients with Hepatocellular Carcinoma

Objective To compare the clinical efficacy of TACE and combined with sorafenib in the treatment of postoperative recurrence in patients with hepatocellular carcinoma.Methods From January 2013 to January 2015, 56 patients with postoperative recurrence hepatocellular carcinoma in our hospital on the basis of different trentmend methods were divided into two groups. In control group, 26 cases were treated with TACE alone. In the observation group,30 cases were treated with TACE combined with sorafenib. After treatment, the patients of short-term efficacy, median survival and extrahepatic metastasis were followed up.Results After one-month treatment,the total effective rate of the observation group (66.7%) was better than that of the control group (38.5%),and the difference was statistically significant (P<0.05). Follow up to December 2016, the median survival time was 15.8 months in the observation group, which was higher than that of 10.8 months in the control group (P<0.05). The extrahepatic metastasis rate of the observation group was 3.33% lower than that of the control group (23.08%) (P<0.05).Conclusion TACE combined with sorafenib can effective to extend recurrent tumor progression,increase the survival time,reduce distant metastasis rate,it could benefit the patients with postoperative HCC recurrence.